Bolt Biotherapeutics Reports Q4/FY25 Results, Projects Cash Runway into 2027 Amidst Going Concern
BOLT is trading near its 52-week low of $4.01 (4.6% above the low) on light trading volume (0.2× avg).
Summary
Bolt Biotherapeutics reported Q4/FY25 financial results, projecting its $31.8 million cash balance to fund operations into 2027, a more optimistic outlook than the concurrent 10-K's going concern warning.
Key Events · Earnings and Guidance · BOLT
-
Q4 and Full-Year 2025 Financial Results
Reported collaboration revenue of $7.7 million and a net loss of $33.4 million for the full year 2025, significantly reduced from $63.1 million in 2024.
-
Cash Runway Extended
As of December 31, 2025, the company held $31.8 million in cash, cash equivalents, and marketable securities, which is anticipated to fund operations into 2027. This statement provides a more optimistic outlook on liquidity compared to the concurrent 10-K filing's going concern warning.
-
Operational Efficiency Improvements
Research and Development (R&D) expenses decreased to $28.5 million in 2025 from $57.5 million in 2024, and General and Administrative (G&A) expenses also decreased, primarily due to restructuring plans.
-
Clinical Pipeline Update
Initial clinical data from the BDC-4182 Phase 1 study for gastric and gastroesophageal cancer patients is expected in the third quarter of 2026. Preclinical programs targeting CEA and PD-L1 are on hold pending partnering or funding.
Analysis · BOLT · Life Sciences
This 8-K furnishes the press release detailing Bolt Biotherapeutics' fourth quarter and full-year 2025 financial results and business update. Crucially, the company reported a cash balance of $31.8 million as of December 31, 2025, which it anticipates will fund operations into 2027. This statement provides a more optimistic outlook on liquidity compared to the concurrent 10-K filing, which included a going concern warning citing insufficient cash for the next 12 months. The company also reported reduced operating losses and R&D expenses due to restructuring efforts. Investors should monitor how the company manages its cash and progresses its BDC-4182 Phase 1 study, with initial clinical data expected in Q3 2026, especially given the conflicting cash runway guidance.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BOLT was trading at $4.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8M. The 52-week trading range was $4.01 to $9.66. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.